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Abstract The present exploratory analysis examined the
efficacy, safety, and quality-of-life effects of everolimus
(EVE) ? exemestane (EXE) in the subgroup of patients in
BOLERO-2 whose last treatment before study entry was in the
(neo)adjuvant setting. In BOLERO-2, patients with hormone-
receptor-positive (HR?), human epidermal growth factor
receptor-2-negative (HER2-) advanced breast cancer recur-
ring/progressing after a nonsteroidal aromatase inhibitor
(NSAI) were randomly assigned (2:1) to receive EVE
(10 mg/day) ? EXE (25 mg/day) or placebo (PBO) ? EXE.
The primary endpoint was progression-free survival (PFS) by
local assessment. Overall, 137 patients received first-line
EVE ? EXE (n = 100) or PBO ? EXE (n = 37). Median
PFS by local investigator assessment nearly tripled to
11.5 months with EVE ? EXE from 4.1 months with
PBO ? EXE (hazard ratio = 0.39; 95 % CI 0.25–0.62),
while maintaining quality of life. This was confirmed by
central assessment (15.2 vs 4.2 months; hazard ratio = 0.32;
95 % CI 0.18–0.57). The marked PFS improvement in
patients receiving EVE ? EXE as first-line therapy for dis-
ease recurrence during or after (neo)adjuvant NSAI therapy
supports the efficacy of this combination in the first-line set-
ting. Furthermore, the results highlight the potential benefit of
early introduction of EVE ? EXE in the management of
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HR?, HER2- advanced breast cancer in postmenopausal
patients.
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Abbreviations
ABC1 1st International Consensus Conference for
Advanced Breast Cancer
AE Adverse event
AGO Arbeitsgemeinschaft Gyna¨kologische
Onkologie e.V
AI Aromatase inhibitor
AKT Protein kinase B
ANA Anastrozole
CI Confidence interval
ECOG Eastern Cooperative Oncology Group
ESMO European Society for Medical Oncology
EVE Everolimus
EXE Exemestane
HER2- Human epidermal growth factor receptor-2-
negative
LET Letrozole
HR Hazard ratio
HR? hormone-receptor-positive
HRQoL Health-related quality of life
LHRHa Luteinizing hormone-releasing hormone
analogue
mTOR Mammalian target of rapamycin
NCCN National Comprehensive Cancer Network
NSAI Nonsteroidal aromatase inhibitor
PBO Placebo
PFS Progression-free survival
PI3K Phosphatidylinositol 3-kinase
RECIST Response Evaluation Criteria in Solid Tumors
TDD Time to definitive deterioration
TTP Time to progression
Introduction
The majority of breast cancers are hormone-receptor-
positive (HR?), with up to 75 % expressing estrogen
receptors and/or progesterone receptors [1, 2], whereas
human epidermal growth factor receptor-2 (HER2) is
overexpressed in approximately 15–23 % of breast cancers
[3]. Thus, the majority of breast cancers are HR? and
HER2-negative (HER2-). Endocrine therapy, particularly
aromatase inhibitors (AIs), represents the principal sys-
temic therapy for postmenopausal women with HR?,
HER2- breast cancer in both the adjuvant and advanced
settings [4, 5]. Nonetheless, disease progression may occur
despite continued endocrine therapy (also referred to clin-
ically as endocrine resistance) [6, 7], and has been attrib-
uted, among other mechanisms, to the cross-talk between
estrogen receptor signaling and the phosphatidylinositol
3-kinase (PI3K)/protein kinase B (AKT)/mammalian target
of rapamycin (mTOR) pathway, which is essential for
breast cancer growth, progression, and insensitivity to
endocrine interventions [7–9]. Thus, co-targeting both
signaling pathways may enhance the effectiveness of
endocrine therapy and improve outcomes in patients with
HR?, HER2- advanced breast cancer [7, 10].
The mTOR inhibitor everolimus (EVE) in combination
with exemestane (EXE) was recently approved for the
treatment of postmenopausal women with HR?, HER2-
advanced breast cancer whose disease recurred or pro-
gressed during or after nonsteroidal AI (NSAI) therapy
[11]. This approval was based on the results of the pivotal
BOLERO-2 trial, wherein EVE ? EXE more than doubled
median progression-free survival (PFS) versus placebo
(PBO) plus EXE at 18 months median follow-up [12],
while maintaining health-related quality of life (HRQoL)
[13]. Moreover, consistent efficacy results were observed
in all predefined subgroups [12], including patients with
visceral metastases, patients with bone disease, elderly
patients, and Asian patients [14–17].
The present exploratory analyses evaluated the efficacy,
safety, and HRQoL effects of EVE ? EXE in the subgroup
of patients in the BOLERO-2 trial who received this reg-
imen as first-line therapy for advanced disease.
Methods
Study design and patient population
The BOLERO-2 trial is an international, phase 3, multi-
center, randomized, double-blind, PBO-controlled trial
(ClinicalTrials.gov identifier NCT00863655) that has been
described in detail previously [18]. In brief, postmeno-
pausal women with HR?, HER2-, unresectable, locally
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advanced or metastatic breast cancer recurring or pro-
gressing during or after letrozole or anastrozole were ran-
domized at a 2:1 ratio to receive either EVE (10 mg daily)
or matching PBO in a blinded manner, with open-label
EXE (25 mg daily). For simplicity, the PBO ? EXE arm
will henceforth be referred to as the control arm. Ran-
domization was stratified by the presence or absence of
visceral metastases and sensitivity to prior endocrine
therapy [18]. Treatment continued until disease progres-
sion, development of unacceptable toxicity, or withdrawal
of consent. Written informed consent was obtained from all
patients before enrollment; trial-related approvals were
obtained from the institutional review boards of partici-
pating centers, and the trial was conducted in accordance
with the Good Clinical Practice guidelines, Declaration of
Helsinki, and local regulations. The present analyses
included patients who received EVE ? EXE as first-line
therapy for advanced disease. Patients in this subset may
have received (neo)adjuvant and adjuvant therapy, or
adjuvant therapy only as last therapy before study entry.
Primary and secondary endpoints
Here we report the results of a retrospective and explor-
atory analysis from the BOLERO-2 trial. The primary
endpoint of BOLERO-2 was investigator-assessed PFS
(defined as time from randomization to first documented
progression or death from any cause) per Response Eval-
uation Criteria in Solid Tumors (RECIST), v1.0. Secondary
endpoints included safety, and HRQoL using European
Organization for Research and Treatment of Cancer QLQ-
C30 and BR23 questionnaires [18]. The present analysis
evaluated investigator-assessed and centrally assessed PFS
according to RECIST, v1.0. As with the overall study,
adverse events (AEs) were recorded throughout the trial
and were graded according to the Common Terminology
Criteria for Adverse Events, v3.0.
Statistical analyses
The subset analyses reported in this manuscript are retro-
spective and exploratory. Estimates of PFS were obtained by
Kaplan–Meier method, and hazard ratios and 95 % confi-
dence intervals (CIs) were calculated using an unstratified
Cox proportional hazards model. Time to definitive deteri-
oration (TDD) of the Global Health Status was defined as a
5 % decrease in HRQoL relative to baseline, with no sub-
sequent increase above this threshold, and was estimated by
Kaplan–Meier method; hazard ratios and 95 % CIs were
calculated using an unstratified Cox proportional hazards
model. All analyses were conducted using SAS for Win-
dows, v9.2 (SAS Institute, Cary, NC, USA). All analyses
were based on data at 18 months median follow-up.
Results
Demographics and disposition
Between June 2009 and January 2011, 724 women across
189 centers in 24 countries were randomized to the
BOLERO-2 trial treatment arms (EVE ? EXE, n = 485;
control, n = 239) [18]. Patient baseline characteristics
were well balanced between treatment groups and have
been reported previously [18]. Overall, 19 % of patients
(137 of 724) entered the trial having received (neo)adju-
vant therapy as their last systemic treatment before study
entry. These patients received EVE ? EXE (100 of 485) or
control (37 of 239) as first-line treatment for advanced
breast cancer. Baseline characteristics were well balanced
between the two treatment arms in this subset, including
the presence of visceral metastases (EVE ? EXE, 50 %;
control, 43 %), bone metastases (EVE ? EXE, 65 %;
control, 70 %), and bone-only metastases (EVE ? EXE,
29 %; control, 24 %) at baseline (Table 1).
Efficacy
The efficacy data from this subset were consistent with
outcomes in the overall trial population [12, 13]. Median
PFS was nearly tripled with EVE ? EXE versus control by
local investigator assessment (11.5 vs 4.1 months, respec-
tively; hazard ratio = 0.39; 95 % CI 0.25–0.62) in patients
whose disease recurred during or after (neo)adjuvant
therapy. Median PFS assessed by independent central
review (15.2 vs 4.2 months, respectively; hazard
ratio = 0.32; 95 % CI 0.18–0.57) was consistent with local
assessment (Fig. 1a, b).
Quality of life
In patients who received EVE ? EXE as first-line therapy
for advanced disease, baseline mean Global Health Status
scores were similar between treatment arms (62.8 vs 63.4).
Median TDD in Global Health Status was numerically
longer with EVE ? EXE versus control (11.1 vs
7.2 months, respectively; hazard ratio = 0.69; 95 % CI
0.39–1.22; Fig. 2).
Safety
The safety profile of EVE ? EXE in this subset analysis
was consistent with that of the overall patient population
[12]. The majority of AEs were mild to moderate in
intensity (i.e., grade 1 or 2) and manageable. The most
frequently reported AEs of any grade with EVE ? EXE
were stomatitis (68 %), diarrhea (40 %), and rash (37 %;
Table 2). Among the most frequently reported any grade
Breast Cancer Res Treat (2014) 143:459–467 461
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AEs, the most common AEs of grade 3 or 4 intensity with
EVE ? EXE were hyperglycemia (8 %), stomatitis (4 %),
diarrhea (4 %), and fatigue (3 %). Treatment discontinua-
tion due to AEs was slightly higher with EVE ? EXE
(10 %) compared with control (8 %). In the EVE ? EXE
arm, 74 % of patients had one or more EVE dose reduc-
tions or interruptions and 23 % had one or more EXE dose
reductions or interruptions. In the control arm, 32 % of
patients had one or more PBO dose reductions or inter-
ruptions and 19 % had one or more EXE dose reductions or
interruptions. The majority of dose reductions or inter-
ruptions for both EVE and EXE were due to AEs.
Notably, the median duration of exposure to EVE in this
subset was 31.1 weeks (range 1.0–109.4 weeks), which is
substantially longer than the median duration of exposure
of 23.9 weeks in the overall patient population (range
1.0–123.3 weeks) [12]. However, the median relative dose
intensity of EVE in this subset (85 %) was comparable to
that in the overall population (86 %).
Discussion
In the overall BOLERO-2 trial population, EVE ? EXE
more than doubled the median PFS compared with control
(local assessment 7.8 vs 3.2 months, respectively; hazard
ratio = 0.45; log-rank P \ 0.0001) without compromising
HRQoL (confirmed by central assessment 11.0 vs
4.1 months, respectively; hazard ratio = 0.38; log-rank
P \ 0.0001) [12]. The present subset analysis from
BOLERO-2 demonstrated that EVE ? EXE as first-line
therapy for advanced breast cancer nearly tripled PFS in
patients with HR?, HER2- advanced breast cancer previ-
ously treated with (neo)adjuvant NSAIs.
Notably, guidelines from the 1st International Consen-
sus Conference for Advanced Breast Cancer (ABC1),
European Society for Medical Oncology (ESMO), and
National Comprehensive Cancer Network (NCCN) gener-
ally recommend multiple lines of endocrine therapy before
switching to chemotherapy for patients with HR? advanced
breast cancer [4, 5, 19]. The German Arbeitsgemeinschaft
Gyna¨kologische Onkologie e.V. (AGO) and Canadian
consensus guidelines specifically recommend EVE ?
EXE, fulvestrant, tamoxifen, or EXE for patients who have
recurred during or after adjuvant AI therapy, with
EVE ? EXE reserved for shorter treatment-free intervals
(i.e., no longer endocrine sensitive) [20, 21].
First-line treatment of advanced breast cancer with AIs
(EXE, letrozole, or anastrozole) has demonstrated superior
efficacy compared with tamoxifen, substantially prolonging
median time to progression (TTP)/PFS durations (9.9/10.7
vs 5.8/6.4 months) in postmenopausal women with HR? or
hormone-receptor status unknown, locally advanced or
Table 1 Baseline characteristics in patients whose disease recurred
during or after adjuvant therapy
Characteristics Patients (%)
EVE ? EXE
(n = 100)
Control (PBO ? EXE)
(n = 37)
Median age, years (range) 62 (45–83) 61 (50–82)
Race
Caucasian 68 62
Asian 31 32
Black 0 3
Other 1 3
ECOG performance statusa
0 70 70
1 29 24
2 0 3
Missing 1 3
Measurable diseaseb 67 68
Metastatic site
Visceralc 50 43
Lung 26 22
Liver 25 30
Lung and liver 5 11
Bone 65 70
Bone only 29 24
Other 47 57
Prior NSAI
LET only 25 24
ANA only 69 70
LET and ANA 6 5
ANA or LET as most recent
treatment
98 100
Prior endocrine therapy other than NSAId,e
Prior tamoxifen 21 22
Prior toremifene 1 3
Prior LHRHa 0 3
Prior chemotherapy
[(neo)adjuvant only]e
74 76
Prior radiotherapye 74 78
Number of prior therapiesf
1 or 2 58 57
C3 42 43
Includes patients who also received (neo)adjuvant therapy
ANA Anastrozole, ECOG Eastern Cooperative Oncology Group, EVE ev-
erolimus, EXE exemestane, LET letrozole, LHRHa luteinizing hormone-
releasing hormone analogue, NSAI nonsteroidal aromatase inhibitor, PBO
placebo
a No patients in this subset had ECOG performance status C3
b Measurable disease includes patients with C1 target lesion; all other
patients had C1 mainly lytic bone lesion
c Visceral includes lung, liver, pleural, pleural effusion, peritoneum, and
ascites
d No patients received prior fulvestrant, consistent with its indication for
metastatic disease
e Received in addition to NSAI in the (neo)adjuvant setting
f Includes all previous treatment modalities
462 Breast Cancer Res Treat (2014) 143:459–467
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recurrent disease without prior exposure to NSAIs [22–24].
However, endocrine therapy in patients with HR?, HER2-
advanced breast cancer previously exposed to NSAIs,
whether in the adjuvant or advanced disease setting, gen-
erally results in shorter median TTP or PFS. For example, in
the EFECT trial, median TTP was 3.7 months for both
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fulvestrant (250 mg q 4 weeks) and EXE (P = 0.65) [6].
In addition, median PFS was 3–5 months in the SoFEA trial
(4.4 months for fulvestrant 250 mg q 4 weeks ? anas-
trozole vs 4.8 months for fulvestrant 250 mg q 4 weeks vs
3.4 months for EXE; P = 0.56–0.98) and 6–7 months in
CONFIRM (6.5 months for fulvestrant 500 mg q 4 weeks
and 5.5 months for fulvestrant 250 mg q 4 weeks;
P = 0.006) [25, 26]. Increasingly, NSAIs have become
standard of care in the adjuvant setting. Thus, although both
EXE and fulvestrant may be used for breast cancer recur-
ring after adjuvant NSAI therapy, the efficacy of these
treatments is limited, and additional effective first-line
treatment options are needed for these patients, especially
those whose disease progressed during/after NSAI therapy.
In this context, data from the present subset analysis provide
support for the efficacy of EVE ? EXE as first-line therapy
in HR?, HER2- breast cancer progressing on adjuvant
NSAIs, and suggest that earlier use of this strategy in the
treatment course may lead to greater benefit.
Combinations of endocrine therapies with targeted
agents in the first-line setting for advanced breast cancer
progressing on NSAIs have shown mixed results. The
histone deacetylate inhibitor entinostat plus EXE increased
median PFS by 2 months versus EXE alone in patients
whose disease recurred after adjuvant NSAI treatment or
progressed after first-line NSAI (4.3 vs 2.3 months,
P = 0.055) [27]. In the phase 3 HORIZON trial, temsi-
rolimus, an mTOR inhibitor, plus letrozole versus letrozole
alone failed to improve PFS as first-line therapy in patients
with AI-naive advanced breast cancer [28]. It was sug-
gested that the cyclic dosing regimen (30 mg/day for
5 days/2 weeks) used for oral temsirolimus [28] may not
have achieved adequate suppression of mTOR activity as
observed with a continuous dosing regimen [29]. In addi-
tion, the study populations in the BOLERO-2 and HORI-
ZON trials had a different prior AI exposure. In fact,
approximately 60 % of patients in HORIZON were endo-
crine therapy-naive at study entry [29]. In contrast, the
TAMRAD (a phase 2 study of EVE plus tamoxifen vs
tamoxifen alone in patients with HR?, HER2- advanced
breast cancer after AI therapy) and BOLERO-2 [8, 18]
study populations only included patients who progressed
on a prior AI.
The data presented here demonstrate that HRQoL is
maintained even though a higher rate of AEs was observed
with EVE ? EXE compared with control. In addition,
proactive monitoring and management of AEs are recom-
mended in patients treated with EVE ? EXE to help fur-
ther optimize clinical benefit. Data from the present
exploratory analysis indicate that EVE ? EXE may be an
effective and tolerable first-line therapy for advanced
breast cancer after (neo)adjuvant NSAI treatment. More-
over, EVE ? EXE could offer an additional first-line
treatment option, providing PFS prolongation beyond the
duration that would be expected with endocrine therapy
alone, which is currently the recommended standard of care
in this patient population [4, 5]. Limitations of this subset
analysis include its retrospective and exploratory nature
and modest sample size. Analysis of outcomes based on
prior use of endocrine therapy only versus endocrine
therapy plus chemotherapy in this subset also was not
considered feasible because of the small sample size and
the risk of creating an imbalance between treatment arms
in further subanalyses.
These data raise a possible hypothesis that EVE ? EXE
combination therapy may be more effective in patients
exposed to multiple lines of endocrine therapy, including
those whose only prior therapy was an NSAI in the adjuvant
setting. Specifically, the disease may be using alternative
pathways, such as the mTOR pathway, to continue cancer
cell growth and proliferation in the presence of endocrine
interventions. These alternative pathways are less likely to
be active in patients with minimal or no prior exposure to
systemic endocrine therapy [29, 30]. Nonetheless, disease
relapse during standard adjuvant endocrine therapy remains
a concern, and might involve similar signaling pathways.
Several prospective trials are also evaluating the effec-
tiveness of EVE in improving disease-free survival and
overall survival when used in combination with endocrine
therapy in the adjuvant setting. For example, the SWOG/
NSABP S1207 study is a phase 3 randomized trial that is
evaluating the efficacy of 1 year of EVE plus endocrine
Table 2 Most commonly reported AEs in patients whose disease
recurred during or after adjuvant therapy (incidence C25 % in the
EVE ? EXE arm)
AE (preferred term) Patients (%)
EVE ? EXE
(n = 100)
Control (PBO ? EXE)
(n = 37)
Grade Grade
All 3 4 All 3 4
Stomatitis 68 4 0 22 0 0
Diarrhea 40 3 1 22 0 0
Rash 37 0 0 8 0 0
Fatigue 32 3 0 16 3 0
Weight decrease 30 1 0 11 0 0
Decreased appetite 28 0 0 11 0 0
Nausea 28 0 1 30 3 0
Cough 26 0 0 8 0 0
Pneumonitisa 22 1 0 0 0 0
Hyperglycemiaa 17 7 1 3 3 0
Includes patients who also received (neo)adjuvant therapy
AE Adverse event, EVE everolimus, EXE exemestane, PBO placebo
a Incidence \25 %, but AE of special interest
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therapy in patients with high-risk early HR?, HER2- breast
cancer [31, 32]. The UNIRAD study by the UNICANCER
group is evaluating the efficacy of EVE when administered
concurrently with endocrine therapy after 3 years of adju-
vant endocrine therapy in a similar study population [33,
34].
Based on data from BOLERO-2, recent NCCN and
Canadian Consensus clinical practice guidelines have rec-
ommended EVE ? EXE therapy for HR?, HER2-
advanced breast cancer recurring/progressing during or after
an NSAI, even in the presence of visceral metastases [19,
21]; however, it should be noted that these guidelines are not
specific to progression during or after adjuvant therapy.
Furthermore, an ongoing multicenter, open-label, single-
arm, phase 2 trial (BOLERO-4) is prospectively evaluating
the efficacy of EVE plus letrozole as first-line therapy in
patients with HR?, HER2- advanced breast cancer [35], and
may provide additional insight into the efficacy of EVE plus
an AI as first-line treatment for advanced disease. Notably,
BOLERO-4 also is evaluating measures to proactively
manage common AEs (e.g., stomatitis) during EVE treat-
ment to maintain continuity of therapy. In addition, the
promising efficacy of EVE in managing advanced breast
cancer has resulted in the ongoing SWOG and UNIRAD
trials (discussed earlier) evaluating the efficacy of adding
EVE to adjuvant endocrine therapy for reducing the risk of
disease recurrence in patients with high-risk early breast
cancer [31–34].
Conclusions
In the BOLERO-2 trial, the benefit of adding EVE to EXE
observed in the subset of patients whose disease progressed
during or after (neo)adjuvant NSAI therapy was consistent
with that observed in the overall population. Furthermore,
the substantial improvement in PFS in this subset was
accomplished while maintaining HRQoL. The safety and
tolerability profile of EVE in this subset analysis also was
similar to that observed in the overall BOLERO-2 popu-
lation and with prior experience in the oncology setting.
These data support the efficacy of EVE ? EXE as first-line
therapy for advanced breast cancer in patients with recur-
rence on adjuvant NSAI therapy.
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